Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

This is a single-arm, prospective clinical study to evaluate the efficacy and safety of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.

Trial Details

NCT ID
NCT07022223
Phase
PHASE2
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
RECRUITING
Cancer Type
Marginal Zone Lymphoma Lymphoma
Interventions
  • orelabrutinib combined with rituximab regimen
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Dongyang, China|29.26778,120.22528
  • Hangzhou, China|30.29365,120.16142
  • Hangzhou, China|30.29365,120.16142
  • Huzhou, China|30.8703,120.0933

Key Eligibility Criteria

  • Age ≥ 18 years, regardless of gender;
  • Histologically confirmed CD20-positive marginal zone lymphoma, including MALT, SMZL, and NMZL, with at least one lesion outside the spleen measurin…
  • MZL that has progressed or relapsed after prior local therapy (including surgery, radiotherapy, anti-Helicobacter pylori treatment, and anti-hepati…
  • ECOG performance status of 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Marginal Zone Lymphoma Lymphoma Trials on Trialify →